New hope for Hard-to-Treat pancreatic cancer: targeted combo trial launches

NCT ID NCT06770452

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a new drug combination for people with advanced pancreatic cancer that has a specific mutation called KRAS G12D. The treatment combines HRS-4642 (a drug that targets the mutated protein), nimotuzumab (an antibody that blocks a growth signal), and standard chemotherapy. The study aims to see how well this combo shrinks tumors and controls the disease in 32 patients who have not had prior treatment for advanced cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-4642 (a KRAS G12D inhibitor) combined with nimotuzumab (an EGFR-targeting antibody) and chemotherapy (gemcitabine + nab-paclitaxel)
What this could lead to: If successful, this could offer a new first-line treatment option for people with advanced pancreatic cancer that has a specific KRAS G12D mutation.
What could go wrong: This is a small, early-phase (Phase 2) single-arm study with no comparison group, so results may not be definitive. The combination may cause significant side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC CARCINOMA

Contacts and locations

Locations

First Affiliated Hospital of Zhejiang University Schlool of Medicine
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310000, China
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.